GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advanced Proteome Therapeutics Corp (TSXV:APC.H) » Definitions » Debt-to-Revenue

Advanced Proteome Therapeutics (TSXV:APC.H) Debt-to-Revenue : N/A (As of Apr. 2023)


View and export this data going back to 1989. Start your Free Trial

What is Advanced Proteome Therapeutics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Advanced Proteome Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Apr. 2023 was C$0.04 Mil. Advanced Proteome Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Apr. 2023 was C$0.00 Mil. Advanced Proteome Therapeutics's annualized Revenue for the quarter that ended in Apr. 2023 was C$0.00 Mil.


Advanced Proteome Therapeutics Debt-to-Revenue Historical Data

The historical data trend for Advanced Proteome Therapeutics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Proteome Therapeutics Debt-to-Revenue Chart

Advanced Proteome Therapeutics Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Advanced Proteome Therapeutics Quarterly Data
Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Advanced Proteome Therapeutics's Debt-to-Revenue

For the Biotechnology subindustry, Advanced Proteome Therapeutics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Proteome Therapeutics's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advanced Proteome Therapeutics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Advanced Proteome Therapeutics's Debt-to-Revenue falls into.



Advanced Proteome Therapeutics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Advanced Proteome Therapeutics's Debt-to-Revenue for the fiscal year that ended in Jul. 2022 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.135 + 0.294) / N/A
=N/A

Advanced Proteome Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Apr. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Apr. 2023) Revenue data.


Advanced Proteome Therapeutics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Advanced Proteome Therapeutics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced Proteome Therapeutics (TSXV:APC.H) Business Description

Traded in Other Exchanges
Address
8337 Eastlake Drive, Suite 104, Burnaby, BC, CAN, V5A 4W2
Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.

Advanced Proteome Therapeutics (TSXV:APC.H) Headlines

No Headlines